Cargando…

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation

Background: Atrial fibrillation (AF) is a common clinical problem and potent risk factor for stroke. However, real-world effectiveness and outcomes for AF patients are not well described. Objective: To compare the economic and clinical impact of stroke and warfarin use on patients with nonvalvular a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Li, Fritschel, Elyse, Baser, Onur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2013
Materias:	Cardiovascular Conditions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471395/ https://www.ncbi.nlm.nih.gov/pubmed/37664149 http://dx.doi.org/10.36469/9852

Ejemplares similares

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
por: Peacock, W. Frank, et al.
Publicado: (2019)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation
por: Reynolds, Matthew R., et al.
Publicado: (2014)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism
por: Wang, Li, et al.
Publicado: (2019)

Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
por: Khaykin, Yaariv, et al.
Publicado: (2016)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients
por: Song, Ziliang, et al.
Publicado: (2020)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation
por: Shang, Luxiang, et al.
Publicado: (2021)

The Association of Economic Outcome and Geriatric Syndromes among Older Adults with Transcatheter Aortic Valve Replacement (TAVR)
por: Kwak, Min Ji, et al.
Publicado: (2020)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
por: Granero Xiberta, Xavier, et al.
Publicado: (2016)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey
por: Arnold, Renée JG, et al.
Publicado: (2015)

Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bitar, Yasmin de Souza Lima, et al.
Publicado: (2021)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Nomogram to Predict Left Atrial Thrombus or Spontaneous Echo Contrast in Patients With Non-valvular Atrial Fibrillation
por: Li, Zhitong, et al.
Publicado: (2021)

Left Atrial Thrombus in Patients With Non-valvular Atrial Fibrillation: A Cross-Sectional Study in China
por: Shi, Shaobo, et al.
Publicado: (2022)

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
por: Pink, Joshua, et al.
Publicado: (2011)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation
por: Pengo, Vittorio, et al.
Publicado: (2015)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

The value of left atrial longitudinal strain in evaluating left atrial appendage spontaneous echo contrast in non-valvular atrial fibrillation
por: Ma, Chang sheng, et al.
Publicado: (2023)

SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S(4)-BOW-AF)
por: Harris, Daniel E, et al.
Publicado: (2023)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

The Cost Effectiveness of Hand Held Ultrasound Scanning for Abdominal Aortic Aneurysm in Older Males with a History of Smoking
por: Phiri, Denver, et al.
Publicado: (2013)

Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
por: Kodama, Kazuhisa, et al.
Publicado: (2020)

A Systematic Literature Review of Three Stenting Strategies for Bifurcation Lesions in Coronary Artery Disease
por: Parsley-Raines, Larragem, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jur4k84t1hho56ruec17h2nm04